CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Lipid modification - primary and secondary CVD prevention - Management
When should I offer lipid modification therapy for primary prevention of cardiovascular disease?
- Offer lipid-modification therapy if the person's estimated 10-year risk of developing cardiovascular disease (CVD) is 20% or more. See the CKS topic on CVD risk assessment and management for information on how to estimate CVD risk.
In depth
© NHS Institute for Innovation and Improvement